Matinas BioPharma Holdings Inc
matinasbiopharma.comWhat Do They Do?
Develops an oral antifungal drug candidate using its lipid nanocrystal delivery platform for patients with invasive fungal infections.
10-K for FY2025, filed Mar 31, 2026Matinas BioPharma Holdings, Inc. (“Matinas” or the “Company”) is a clinical-stage biopharmaceutical company focused on delivering…View ↗
Our lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been…View ↗
Our lead drug candidate based on the LNC Platform is MAT2203, an oral formulation of amphotericin B, a well-known and highly effective…View ↗
The initial planned indication for MAT2203 is early step-down therapy from IV amphotericin B for the treatment of invasive aspergillosis in…View ↗
How Do They Make Money?
$1.1M
-
10-K for FY2024, filed Apr 15, 2025
$1.1M ↗
Do Revenues Turn Into Profits?
No. It lost $22.9M in FY2023.
10-K for FY2024, filed Apr 15, 2025
−$23.8MView ↗
10-K for FY2024, filed Apr 15, 2025
−$22.9MView ↗
10-K for FY2024, filed Apr 15, 2025
−$15.5MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$1.3MView ↗
- ▼ −75% (Loss)
- vs −$5.2M in Q2 FY2025
-
Jul 13, 2026
Agrees to merge with GH Power and sell MAT2203 and its LNC platform
The sale to Azurity includes $4.0 million upfront, up to $17.5 million in potential milestones, and future mid-single-digit royalties.
Sources
8-K, filed Jul 13, 2026
Definitive agreement provides for the sale of Matinas BioPharma Nanotechnologies, Inc., including MAT2203 and the LNC technology platform…View ↗
Growing. Revenue grew 12.2x in 4 years, from $89.8K in FY2019 to $1.1M in FY2023, about 87% a year.
Narrower development focus
The older report described internal nucleic-acid programs and partner collaborations using the platform; the latest report says internal pipeline work is paused as the company seeks a partner for its lead drug candidate and evaluates strategic alternatives.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 31, 2026
Planned treatment focus
The older report described cryptococcal meningitis as the initial planned use; the latest report identifies invasive aspergillosis as the initial planned indication.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 31, 2026The initial planned indication for MAT2203 is as step-down therapy from IV amphotericin B for the treatment of cryptococcal meningitis…View ↗
The initial planned indication for MAT2203 is early step-down therapy from IV amphotericin B for the treatment of invasive aspergillosis in…View ↗
Who Do They Compete With?
Competes with Merck, Pfizer, Astellas Pharma US, Jansen Pharmaceuticals, Leadiant Biosciences, CorMedix Therapeutics, GlaxoSmithKline, X-Gen Pharmaceuticals, F2G, Basilea, and Elion Therapeutics
10-K for FY2025, filed Mar 31, 2026MAT2203, if approved by FDA, will primarily compete with antifungal classes approved for the treatment of fungal and mold infections, which…View ↗
Loading...
